Zabinostat (CXD101) is a novel epigenetic regulator with immune-regulatory properties. It is an orally available small molecule with anti-tumour properties and a well-tolerated safety profile in humans. It allows tumour cells to be recognised by the immune system and has shown efficacy in colorectal cancer and lymphomas.
Emactuzumab (CXD301) is a humanised recombinant monoclonal antibody directed against the Colony Stimulating Factor-1 Receptor expressed on tumour-associated M2 macrophages. It effectively depletes CSF-1R positive macrophages in the tumour microenvironment.